FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223537410> ?p ?o ?g. }

• W4223537410 endingPage "1789" @default.
• W4223537410 startingPage "1776" @default.
• W4223537410 abstract "Abstract Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investigating the recommended phase 2 dose (RP2D) and activity of entrectinib in pediatric patients with solid tumors including primary central nervous system tumors. Methods STARTRK-NG (NCT02650401) is a phase 1/2 trial. Phase 1, dose-escalation of oral, once-daily entrectinib, enrolled patients aged &lt;22 years with solid tumors with/without target NTRK1/2/3, ROS1, or ALK fusions. Phase 2, basket trial at the RP2D, enrolled patients with intracranial or extracranial solid tumors harboring target fusions or neuroblastoma. Primary endpoints: phase 1, RP2D based on toxicity; phase 2, objective response rate (ORR) in patients harboring target fusions. Safety-evaluable patients: ≥1 dose of entrectinib; response-evaluable patients: measurable/evaluable baseline disease and ≥1 dose at RP2D. Results At data cutoff, 43 patients, median age of 7 years, were response-evaluable. In phase 1, 4 patients experienced dose-limiting toxicities. The most common treatment-related adverse event was weight gain (48.8%). Nine patients experienced bone fractures (20.9%). In patients with fusion-positive tumors, ORR was 57.7% (95% CI 36.9-76.7), median duration of response was not reached, and median (interquartile range) duration of treatment was 10.6 months (4.2-18.4). Conclusions Entrectinib resulted in rapid and durable responses in pediatric patients with solid tumors harboring NTRK1/2/3 or ROS1 fusions." @default.
• W4223537410 created "2022-04-15" @default.
• W4223537410 creator A5004458586 @default.
• W4223537410 creator A5006237826 @default.
• W4223537410 creator A5009723460 @default.
• W4223537410 creator A5016432846 @default.
• W4223537410 creator A5019837009 @default.
• W4223537410 creator A5022484449 @default.
• W4223537410 creator A5024176070 @default.
• W4223537410 creator A5035557509 @default.
• W4223537410 creator A5039864062 @default.
• W4223537410 creator A5040815350 @default.
• W4223537410 creator A5045026723 @default.
• W4223537410 creator A5047528677 @default.
• W4223537410 creator A5047711490 @default.
• W4223537410 creator A5050738935 @default.
• W4223537410 creator A5052721722 @default.
• W4223537410 creator A5057088025 @default.
• W4223537410 creator A5059333410 @default.
• W4223537410 creator A5061278042 @default.
• W4223537410 creator A5064788392 @default.
• W4223537410 creator A5068808085 @default.
• W4223537410 creator A5073092034 @default.
• W4223537410 creator A5075174884 @default.
• W4223537410 creator A5079162505 @default.
• W4223537410 creator A5082405249 @default.
• W4223537410 creator A5083774265 @default.
• W4223537410 creator A5085820190 @default.
• W4223537410 creator A5087598270 @default.
• W4223537410 creator A5088462429 @default.
• W4223537410 creator A5088553415 @default.
• W4223537410 date "2022-04-08" @default.
• W4223537410 modified "2023-10-10" @default.
• W4223537410 title "Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)" @default.
• W4223537410 cites W2019607817 @default.
• W4223537410 cites W2070550035 @default.
• W4223537410 cites W2104320396 @default.
• W4223537410 cites W2148417205 @default.
• W4223537410 cites W2162643152 @default.
• W4223537410 cites W2194206428 @default.
• W4223537410 cites W2497876629 @default.
• W4223537410 cites W2587443662 @default.
• W4223537410 cites W2601373079 @default.
• W4223537410 cites W2678747063 @default.
• W4223537410 cites W2742224451 @default.
• W4223537410 cites W2765750906 @default.
• W4223537410 cites W2797653167 @default.
• W4223537410 cites W2896424462 @default.
• W4223537410 cites W2897305758 @default.
• W4223537410 cites W2900674461 @default.
• W4223537410 cites W2907142640 @default.
• W4223537410 cites W2975995592 @default.
• W4223537410 cites W2982198358 @default.
• W4223537410 cites W2995220921 @default.
• W4223537410 cites W2996574710 @default.
• W4223537410 cites W3008107700 @default.
• W4223537410 cites W3014806119 @default.
• W4223537410 cites W3020913855 @default.
• W4223537410 cites W3120665670 @default.
• W4223537410 cites W3121992590 @default.
• W4223537410 cites W3135209648 @default.
• W4223537410 cites W3198492017 @default.
• W4223537410 cites W3200255249 @default.
• W4223537410 cites W4205109259 @default.
• W4223537410 cites W4250124534 @default.
• W4223537410 doi "https://doi.org/10.1093/neuonc/noac087" @default.
• W4223537410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35395680" @default.
• W4223537410 hasPublicationYear "2022" @default.
• W4223537410 type Work @default.
• W4223537410 citedByCount "29" @default.
• W4223537410 countsByYear W42235374102022 @default.
• W4223537410 countsByYear W42235374102023 @default.
• W4223537410 crossrefType "journal-article" @default.
• W4223537410 hasAuthorship W4223537410A5004458586 @default.
• W4223537410 hasAuthorship W4223537410A5006237826 @default.
• W4223537410 hasAuthorship W4223537410A5009723460 @default.
• W4223537410 hasAuthorship W4223537410A5016432846 @default.
• W4223537410 hasAuthorship W4223537410A5019837009 @default.
• W4223537410 hasAuthorship W4223537410A5022484449 @default.
• W4223537410 hasAuthorship W4223537410A5024176070 @default.
• W4223537410 hasAuthorship W4223537410A5035557509 @default.
• W4223537410 hasAuthorship W4223537410A5039864062 @default.
• W4223537410 hasAuthorship W4223537410A5040815350 @default.
• W4223537410 hasAuthorship W4223537410A5045026723 @default.
• W4223537410 hasAuthorship W4223537410A5047528677 @default.
• W4223537410 hasAuthorship W4223537410A5047711490 @default.
• W4223537410 hasAuthorship W4223537410A5050738935 @default.
• W4223537410 hasAuthorship W4223537410A5052721722 @default.
• W4223537410 hasAuthorship W4223537410A5057088025 @default.
• W4223537410 hasAuthorship W4223537410A5059333410 @default.
• W4223537410 hasAuthorship W4223537410A5061278042 @default.
• W4223537410 hasAuthorship W4223537410A5064788392 @default.
• W4223537410 hasAuthorship W4223537410A5068808085 @default.
• W4223537410 hasAuthorship W4223537410A5073092034 @default.
• W4223537410 hasAuthorship W4223537410A5075174884 @default.
• W4223537410 hasAuthorship W4223537410A5079162505 @default.
• W4223537410 hasAuthorship W4223537410A5082405249 @default.
• W4223537410 hasAuthorship W4223537410A5083774265 @default.

• next